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M A J O R A R T I C L E
Prevalence and Clinical Correlates of YMDD
Variants during Lamivudine Therapy for Patients
with Chronic Hepatitis B
Ching-Lung Lai,1 Jules Dienstag,3 Eugene Schiff,4 Nancy W. Y. Leung,2 Mark Atkins,6 Christine Hunt,5
Nathaniel Brown,5 Mary Woessner,5 Richard Boehme,5 and Lynn Condreay5
1University Department of Medicine, Queen Mary Hospital, and 2Department of Medicine and Therapeutics, Prince of Wales Hospital, Hong Kong;
3Gastrointestinal Unit (Medical Services), Massachusetts General Hospital and Department of Medicine, Harvard Medical School, Boston,
Massachusetts; 4Center for Liver Diseases, University of Miami School of Medicine, Miami, Florida; 5GlaxoSmithKline, Research Triangle Park,
North Carolina; and 6GlaxoSmithKline, Greenford, United Kingdom
YMDD variants of hepatitis B virus (HBV) emerge in some patients with chronic hepatitis B who receive
lamivudine. YMDD variants were examined in 794 patients in 4 controlled studies of 1 year’s duration. The
long-term effects of YMDD variants were examined in a subset of patients treated up to 4 years. YMDD
variants were detected by polymerase chain reaction (PCR) and restriction fragment-length polymorphism
assays. After 1 year, YMDD variants were detected in 81 (24%) of 335 patients. In these patients, the median
serum HBV DNA concentration at 1 year was !20% of the baseline level, and serum alanine transaminase
(ALT) levels and liver histologic findings had significantly improved. In patients with YMDD variants who
were treated for up to 4 years, median HBV DNA and ALT levels showed improvements. Sex, baseline body
mass index, and HBV DNA level were associated with emergence of YMDD variants. Patients with YMDD
variants losing clinical response with a significant increase in the HBV DNA and ALT levels may require
additional therapy.
Viral quasi species in chronic viral infections may con-
tain variants that evade host immune responses or resist
antiviral-agent inhibition [1–7]. Such resistant variants
that emerge during HIV infection are associated with
disease progression [8]; however, in patients with
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chronic hepatitis B, the link between emergence of var-
iants and progression of liver disease is less predictable
[9].
Hepatitis B virus (HBV) replication requires the ac-
tivity of HBV DNA polymerase [10], the molecular
target of antiviral nucleoside analogues [11]. Sponta-
neous polymerase mutations occur naturally. HBV
polymerase does not have a proofreading mechanism
[12, 13]; therefore, the fidelity of replication is imper-
fect. Prolonged therapy with the nucleoside analog la-
mivudine selects for HBV variants with amino acid
changes in the YMDD motif (tyrosine [Y], methionine
[M], aspartate [D], and aspartate [D] amino acid res-
idues at position 552 of the HBV DNA polymerase) of
the polymerase protein [14] that have 110,000-fold re-
duced susceptibility to lamivudine in vitro [15, 16].
Compared with wild-type HBV, however, YMDD var-
iants have reduced affinity for nucleotide substrates
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Table 1. Clinical studies of patients with hepatitis B who received lamivudine therapy.
Study Study group and criteria Location of study Study design Treatment arm
B3009 [7] 358 Patients who were not previously
treated for hepatitis B; enrollment
required abnormal liver histologic find-
ings but permitted normal baseline
alanine aminotransferase levels
Hong Kong, Singa-
pore, Taiwan
Randomized, double blind,
placebo controlled
Lamivudine (100 mg once daily) for 12 months
(n p 143); lamivudine (25 mg once daily)
for 12 months (n p 142); placebo for 12
months (n p 73)
A3010 [20] 141 Patients who had not previously
been treated for hepatitis B
United States Randomized, double blind,
placebo controlled
Lamivudine (100 mg once daily) for 12 months
(n p 70); placebo for 12 months (n p 71)
B3010 [21] 230 Patients who had not previously
been treated with IFN for hepatitis B
Europe, Canada,
South Africa, Aus-
tralia, New Zealand
Randomized, partially
blinded
Lamivudine (100 mg once daily) for 12 months
(n p 84); IFN-a (10 MU 3 times weekly; 2
months of placebo, followed by 4 months
of IFN-a; n p 70); lamivudine–IFN-a combi-
nation (2 months of lamivudine, followed by
4 months of combination therapy; n p 76)
AB3011 [22] 238 Patients whose illness failed to
respond to IFN-a therapy
United States, Europe Randomized, placebo con-
trolled, partially blinded
Lamivudine (100 mg once daily) for 12 months
(n p 119); placebo for 12 months (n p 56);
lamivudine–IFN-a combination (2 months of
lamivudine, followed by 4 months of combi-
nation therapy; n p 63)
B3018 [23, 24] 331 Patients; continuation of protocol for
patients who completed study B3009
Hong Kong, Singa-
pore, Taiwan
Randomized, double blind,
placebo controlled
Lamivudine (100 mg once daily) for 12 months
(n p 133); lamivudine (25 mg once daily)
for 12 months (n p 132); placebo (n p 66)a
a Patients who received lamivudine in B3009 were randomized to continue therapy or to switch to placebo; patients who received placebo in B3009 received
lamivudine (100 mg) in B3018. Four-year data refer to the 58 patients assigned to receive 5 years of therapy with lamivudine (100 mg).
[17], circulate at lower serum titers [18], and appear to be
functionally impaired, with potentially less capacity for causing
disease.
Controlled clinical trials involving patients receiving lami-
vudine therapy provided an opportunity to investigate the fre-
quency of YMDD variants as well as the impact of these variants
on virologic, biochemical, and histologic outcomes associated
with therapy [19]. In this report, we assess the prevalence of
YMDD variants during lamivudine therapy, the effect of these
variants on drug efficacy and safety, and host variables that
influence their emergence.
PATIENTS AND METHODS
Patient populations. Data from 4 multicenter, controlled,
phase 3 trials [7, 20–22] were combined to yield a study pop-
ulation comprising 967 patients, 558 of whom received lami-
vudine monotherapy for 1 year (table 1). Entry criteria included
chronic hepatitis B surface antigen (HBsAg) and hepatitis B e
antigen (HBeAg) seropositivity for 16 months, HBV DNA de-
tectability (by the Abbott Genostics solution hybridization as-
say), a serum alanine aminotransferase (ALT) level !10 times
the upper limit of normal, age of 118 years, and no evidence
of hepatic decompensation. Most patients in the Asian mul-
ticenter study B3009 [7] were enrolled into a follow-up study,
study B3018 [23, 24], for up to 208 weeks; we included them
to assess YMDD variants in patients undergoing extended la-
mivudine therapy. Studies were approved by local ethics com-
mittees, and all patients provided written, informed consent
before enrolling in the follow-up study.
Analysis of HBV variants. In the 4 phase 3 studies, HBV
variant analyses were performed on serum samples at study
week 52 or at the end of treatment and 12–16 weeks after
completion of treatment. Patients in whom YMDD variants
were detected at week 52 were tested to determine when the
variants first appeared. HBV variants were determined by PCR
amplification of DNA extracted from serum samples with a
restriction fragment-length polymorphism assay [25] that can
detect variant or wild-type virus in a mixed population if either
is present as 5% of the total population.
Statistical methods. Data from the 4 phase 3 studies were
integrated to examine the effect of YMDD variants on the
following protocol-defined end points: histologic response (2
point decrease between baseline and week 52 in histologic ac-
tivity index [HAI]), HBeAg seroconversion (loss of HBeAg and
acquisition of antibody [anti-HBe]), serum ALT level (2 con-
secutive normal ALT measurements obtained 7 days apart,
in patients with elevated baseline ALT levels), serum HBV DNA
(loss of detectable serum HBV DNA, as determined by solution
hybridization assay), and safety parameters (serious adverse
event [SAE], as defined by World Health Organization criteria)
after 1 year of lamivudine therapy. “Continued” HBV DNA or
ALT responses were defined as HBV DNA or ALT responses
maintained subsequently with no 2 consecutive detectable HBV
DNA measurements or abnormal ALT values and with unde-
tectable HBV DNA or normal ALT values at week 52.
Results were presented as the proportion of patients with a
response displayed by treatment group (the placebo group, the
lamivudine variant group, and the lamivudine nonvariant
group). Exploratory logistic regression analyses were prepared
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Table 2. Hepatitis B virus (HBV) genotypes found after 1–4 years of lamivudine
therapy.
Study
No. (%) of patients
HBV DNA
negative
Infected with
wild-type HBV
Infected with
mixed
HBV typea
Infected with
YMDD-variant
HBVb
Integrated 1-year datac 63 (19) 191 (57) 33 (10) 48 (14)
A3010d 9 (20) 21 (48) 1 (2) 13 (30)
B3010d 13 (21) 29 (48) 8 (13) 11 (18)
AB3011d 34 (34) 38 (38) 10 (10) 17 (17)
B3009d,e 7 (5) 103 (79) 14 (11) 7 (5)
B3018, study yearf
2 (n p 74) 17 (23) 26 (35) 7 (9) 24 (32)
3 (n p 51) 10 (20) 14 (27) 10 (20) 17 (33)
4 (n p 43) 5 (12) 8 (19) 12 (28) 18 (42)
a Both YMDD-variant HBV and wild-type HBV were detectable.
b Only YMDD-variant HBV was detectable.
c Combined data after 1 year of therapy in A3010, B3010, AB3011, and the lamivudine (100 mg)
group in B3009.
d After 1 year of therapy.
e Study of therapy with lamivudine, 100 mg/day.
f Data refer to patients randomized to receive 5 years of therapy with lamivudine (100 mg).
Figure 1. Proportion of patients infected with mixed wild-type and
YMDD-variant hepatitis B virus (HBV) or YMDD-variant HBV that was
detected at the end of 52 weeks of lamivudine therapy and at the end
of 12 or 16 weeks’ posttreatment follow-up (integrated phase 3 data).
to assess efficacy responses observed in the lamivudine variant
and nonvariant groups. Because the groups being compared in
the integrated 1-year analysis were not randomized, baseline
variables were adjusted in comparing the variant and nonvar-
iant subgroups. In addition, pairwise correlations between ef-
ficacy parameters and the presence or absence of variants were
presented to explore which efficacy parameters were affected
by YMDD variants. Similar analyses were performed to com-
pare the lamivudine-variant group to the placebo group. We
also performed logistic regression analyses to explore the effects
of baseline and demographic variables as predictors of YMDD-
variant development.
Samples of HBV DNA were categorized as wild type, YMDD
variant, mixed (wild-type and YMDD variants detected), or
DNA-negative (HBV DNA undetectable by PCR). For most
analyses, YMDD-variant and mixed categories were combined
as YMDD-variant, whereas wild-type and DNA-negative cat-
egories were combined as nonvariant.
RESULTS
Incidence of YMDD Variants
Serum samples were available for analysis from 794 of the 967
study patients. Of the 558 patients who received lamivudine
monotherapy in the 1-year phase 3 studies, 468 (84%) were
analyzed for the presence of HBV variants at week 52. The
overall 1-year incidence of YMDD variants in the lamivudine
group ( ) was 24%, ranging in individual studies fromnp 426
15% to 32%, with the lowest in the Asian trial [7] (table 2).
YMDD variants, which were identified only in patients receiving
lamivudine monotherapy (never in recipients of placebo, in-
terferon monotherapy, or 6 months of lamivudine-interferon
combination therapy), were seldom detected before 36 weeks
of therapy.
Among the 93 patients treated with lamivudine (100 mg)
for 2 years, YMDD variants were detectable in 31 (42%) of the
74 with data available for analysis at week 104 [23]. Among
the 58 patients randomized to receive 4 years of lamivudine,
YMDD variants were detectable in 53% and 70% after 3 and
4 years, respectively [24]. In the only study comparing lami-
vudine doses of 25 mg and 100 mg [7], the 1-year incidences
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Table 3. Effects of YMDD variants on protocol-defined re-
sponses (1-year integrated data).
Response
Placebo
group
Lamivudine group
YMDD-variant
HBV
Nonvariant
HBV
HAI response 48/156 (31) 43/84 (51)a 199/324 (61)a
HBeAg seroconversion 16/196 (8) 8/100 (8) 75/363 (21)b
Continued ALT
response 25/173 (14) 28/96 (29)c 192/279 (69)d
Continued HBV DNA
response 22/194 (11) 15/99 (15)e 188/346 (54)d
NOTE. Data are no. of patients with response/no. of patients who received
agent or placebo (%). ALT, alanine aminotransferase; HAI, histologic activity
index; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus.
a , compared with the placebo group.P ! .003
b , compared with the YMDD-variant group.P ! .006
c , compared with the placebo group (adjusted for baseline factors).P ! .005
d , compared with the YMDD-variant group.P ! .001
e , compared with the placebo group (adjusted for baseline factors).Pp .04
Figure 2. Proportion of patients with hepatitis B e antigen seroconversion at the end of 1–4 years of therapy with lamivudine (100 mg), analyzed
with respect to whether YMDD-variant hepatitis B virus was detectable (Asian extended treatment study).
of YMDD variants were 14% (19 of 133 patients) and 16% (21
of 131 patients), respectively.
YMDD variants were detectable in fewer patients at the end
of a 12–16-week posttreatment follow-up period compared
with the end of therapy (figure 1). Moreover, most patients
with YMDD variants at the end of follow-up had mixed wild-
type/YMDD-variant HBV, whereas fully YMDD variant pop-
ulations were more common at the end of therapy. Thus, when
lamivudine therapy was stopped, YMDD-variant HBV tended
to revert to wild-type HBV.
Effects of YMDD Variants on Efficacy End Points
HBeAg seroconversion. The emergence of YMDD variants
during 1 year of lamivudine therapy did not preclude HBeAg
seroconversion in phase 3 studies; however, the rate in the
YMDD-variant group was indistinguishable from that in pla-
cebo recipients (table 3). During 1 year of lamivudine therapy,
the nonvariant group had a significantly higher HBeAg sero-
conversion rate than did the YMDD-variant group (21% vs.
8%; ), a difference that continued during 4 years ofP ! .006
lamivudine therapy in study B3018 (figure 2).
Serum ALT level. During 1 year of lamivudine therapy,
the median serum ALT level was lowest in lamivudine-treated
patients in the nonvariant group, and, in lamivudine-treated
patients with YMDD variants, it remained less than that for
placebo recipients (figure 3). These differences persisted as ther-
apy extended to 4 years (figure 4). “Continued” ALT responses
were maintained in lamivudine recipients in the YMDD-variant
group (29%) less frequently than in lamivudine recipients in
the nonvariant group (69%; ) but more frequently thanP ! .001
in placebo recipients (14%; ; table 3).P ! .005
During 1-year studies, the median decrease in the ALT level
was substantially greater in lamivudine recipients regardless of
whether YMDD variants were present (41%) or absent (60%),
compared with placebo recipients (15%). Improved ALT values
persisted in most patients, even with the extended presence of
YMDD variants. Among all patients receiving lamivudine in
study B3018 who acquired YMDD variants, the median ALT
level at the end of 2 years of therapy was less than the baseline
level and within the normal range (table 4); however, the mag-
nitude of improvement diminished as the duration of exposure
to YMDD variants increased. Even among the subset of study
B3018 patients treated for 3 years who harbored YMDD var-
iants for 2 years, the median ALT level remained less than
the baseline level (figure 5).
Serum HBV DNA. In 1-year studies, the median baseline
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Figure 3. Median serum alanine aminotransferase (ALT) level during 1 year of lamivudine therapy in patients with and without detectable YMDD-
variant hepatitis B virus (HBV) infection at the end of the year (integrated phase 3 data). ULN, upper limit of normal.
Figure 4. Median serum alanine aminotransferase (ALT) level during 4 years of lamivudine therapy (Asian extended therapy study). ULN, upper
limit of normal.
HBV DNA value was similar in the placebo (78.5 pg/mL) and
variant-free lamivudine groups (75.4 pg/mL), but it was higher
(137.8 pg/mL) in the YMDD-variant group. Similarly, among
51 patients treated for 3 years, the median baseline HBV DNA
value was 33 pg/mL for the variant-free group, and it was 67
pg/mL for the variant group.
After 1 year of therapy, median HBV DNA concentrations
were 28.5 pg/mL in placebo recipients, 22.0 pg/mL in the
YMDD-variant group, and 1.2 pg/mL (less than the assay’s
detection limit) in the nonvariant group. The median 1-year
decrease in the serum HBV DNA level was 46% in the placebo
group, 81% in the YMDD-variant lamivudine group, and 97%
in the nonvariant lamivudine group. Continued HBV DNA
responses were maintained in the YMDD-variant group (15%)
less frequently than in the nonvariant lamivudine group (54%;
) but more frequently than in the placebo group (11%;P ! .001
; table 3).Pp .04
In study B3018, after 2 years of therapy, 88% of patients in
the YMDD-variant group had HBV DNA levels that were less
than the baseline level. Even among the subset of patients
treated for 3 years who harbored YMDD variants for2 years,
the median HBV DNA level remained less than the baseline
level (figure 6).
Histologic response. In phase 3 studies, 1 year of lami-
vudine therapy improved liver histologic findings significantly
(2 point HAI reduction) compared with placebo, regardless
of whether YMDD variants were detected ( ; table 3).P ! .003
Results of liver biopsies were available at baseline and at the
end of 1 and 3 years of therapy for 13 patients, 9 of whom
harbored YMDD variants at the end of 3 years [25]. Compared
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Table 4. Effects of YMDD variants on alanine aminotransferase
(ALT), bilirubin, and hepatitis B virus (HBV) DNA levels during 2 years
of lamivudine therapy (B3018 study).
Laboratory parameter
Median value (range)
Nonvariant
HBV group
YMDD-variant
HBV group
ALT level, ULN
Baseline 1.2 (0.3–10.8) 1.7 (0.4–15.5)
Week 52 0.7 (0.2–12.3) 0.7 (0.2–27.7)
Week 104 0.6 (0.2–4.5) 0.9 (0.1–9.1)
Bilirubin level, ULN
Baseline 0.5 (0.2–2.5) 0.6 (0.2–1.6)
Week 52 0.5 (0.1–2.2) 0.6 (0.3–2.6)
Week 104 0.5 (0.1–3.1) 0.6 (0.3–1.6)
HBV DNA level, pg/mL
Baseline 78.6 (0.8 to 990.1)a 79.8 (0.8 to 762.7)
Week 52 2.5 (0.8 to 580.2) 1.3 (0.8 to 178.2)
Week 104 0.8 (0.8 to 104.0) 7.3 (0.8 to 128.2)
NOTE. ULN, upper limit of normal.
a The lower limit of detection for the assay is 0.8 pg/mL.
Figure 5. Median serum alanine aminotransferase (ALT) level during 3 years of daily lamivudine (100 mg) therapy (Asian extended therapy study)
in the subset of study participants in whom YMDD variants developed during year 1 of therapy and persisted for 2 years. HBV, hepatitis B virus;
ULN, upper limit of normal.
with baseline, 3-year histologic findings in YMDD-variant pa-
tients were improved in 5 of 9 patients, unchanged in 2 of 9
patients, and worse (2-point HAI increase) in 2 of 9 patients.
Compared with the findings of the year 1 biopsy, however,
histologic findings deteriorated at 3 years in 6 of 9 patients in
the YMDD-variant group.
Effects of YMDD Variants on Safety
Adverse events. In 1-year studies, the incidence of adverse
events (the most frequent of which were viral respiratory in-
fection, malaise or fatigue, abdominal discomfort, cough, and
headache) was similar in lamivudine-treated patients both dur-
ing treatment, with (86 [86%] of 100) or without (294 [80%]
of 368) YMDD variants, and after treatment, with (28 [62%]
of 45) or without (69 [58%] of 119) variants. A slightly higher
frequency of malaise occurred in the YMDD-variant group (37
[37%] of 100) than the nonvariant group (81 [22%] of 368).
With more-prolonged lamivudine therapy (study B3018), the
presence of YMDD variants did not affect the incidence and
nature of adverse events.
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Figure 6. Median serum hepatitis B virus (HBV) DNA level, as measured by hybridization assay, during 3 years of daily lamivudine (100 mg) therapy
(Asian extended therapy study) in the subset of study participants in whom YMDD variants developed during year 1 of therapy and persisted for 2
years. Median HBV DNA values at week 156 were significantly lower than the baseline value ( ) for the YMDD-variant group.P ! .001
Table 5. Elevations in the alanine aminotransferase (ALT) level during and after lamivudine therapy.
ALT response definition
During therapy After therapy
No YMDD
groupa
(n p 362)
Mixed-variant
groupb
(n p 45)
YMDD-variant
groupc
(n p 55)
Placebo
group
(n p 166)
No YMDD
group a
(n p 118)
Mixed-variant
groupb
(n p 12)
YMDD-variant
groupc
(n p 33)
Placebo
group
(n p 52)
2 times the baseline level 16 27 40 30 34 50 6 17
3 times the baseline level 8 20 27 14 25 42 3 6
2 times the baseline level
and 1500 U/L 3 11 13 7 17 42 3 6
2 times the baseline
level; bilirubin level of 12
times the ULN and 2
times the baseline level 0 4 0 !1 2 8 0 2
NOTE. Data are percentage of total patients. HBV, hepatitis B virus; ULN, upper limit of normal.
a Lamivudine treatment group; HBV was wild-type or undetectable.
b Lamivudine treatment group; mixed population of wild-type and YMDD-variant HBV was detected.
c Lamivudine treatment group; only YMDD-variant HBV was detected.
Laboratory parameters. Two-fold and 3-fold ALT eleva-
tions during treatment were more common in patients with
YMDD variants than in those without variants (table 5); how-
ever, no increase in the most severe category of ALT elevation
(i.e., bilirubin elevation) occurred in patients with variants. ALT
elevations that occurred after the completion of treatment were
less common in patients harboring fully variant HBV than
among those harboring either mixed HBV types or nonvariant
HBV.
During year 2 of lamivudine therapy in study B3018, 4 pa-
tients with ALT elevations had concomitant bilirubin elevations
and had YMDD variants at week 104. One event was associated
with HBeAg seroconversion. All events resolved spontaneously.
SAEs. Of 967 patients in the 1-year trials, 12 with YMDD
variants had SAEs reported: 3 ALT elevations (2 with transient
hyperbilirubinemia) when YMDD variants emerged during
treatment and that resolved spontaneously with continued
treatment; 3 posttreatment ALT elevations coinciding with re-
emergence of wild-type HBV in 2 patients (1 of whom had a
transient 14.7-s prothrombin time, a bilirubin level of 2.0 mg/
dL, and later seroconversion after 3 weeks of lamivudine ther-
apy) [26]; 2 instances of asymptomatic emergence of YMDD
variants without ALT elevations (reported by study investigators
as SAEs); and 4 SAEs unrelated to the emergence of the YMDD
variants (drug overdose, ALT elevation 14 days into treat-
ment, elevated creatine phosphokinase level, and symptomatic
cholelithiasis).
In study B3018, SAEs were reported for 16 patients with
YMDD variants in the second year of lamivudine therapy: 14
patients (88%) had ALT elevations that resolved spontaneously
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without change in treatment (1 elevation occurred before treat-
ment, 9 occurred during treatment [5 within 12 weeks after
the first detection of YMDD variants], and 4 occurred after
treatment), and 2 patients had SAEs that were unrelated to the
emergence of the YMDD variants (one patient had creatine
phosphokinase elevation after trauma, and the other had an
adenoid carcinoma). Throughout 4 years of lamivudine therapy
in study B3018, the proportion of patients with liver dis-
ease–related SAEs was similarly low in patients with and with-
out YMDD variants. One death, which was due to acute bac-
terial peritonitis, occurred after the emergence of a YMDD
variant.
Predictors of YMDD Variant Emergence
In 1-year trials, YMDD variants correlated positively with
weight ( ), body mass index ( ), and malePp .0008 Pp .004
sex, baseline HBV DNA level, height, and age ( ). Sex,P ! .10
age, ethnicity, body mass index, cirrhosis, HAI, necroinflam-
matory HAI, ALT level, bilirubin level, and HBV DNA level
were the candidate variables with a significance level of Pp
(specified for inclusion in the model) that were investigated.10
in a stepwise regression analysis. Asian ethnicity ( )Pp .0008
and female sex ( ), the only significant regressors, werePp .01
associated with a lack of emergence of YMDD variants.
In a second regression model, in which ethnicity was re-
moved as a candidate variable to identify alternative explana-
tions for the effect of ethnicity, high baseline HBV DNA level,
high body mass index, and male sex were significant, indepen-
dent predictors ( ) for the emergence of YMDD variants.P ! .03
Male sex correlated significantly ( ) with higher baselineP ! .05
ALT level, HAI, necroinflammatory score, and HBV DNA level,
suggesting that disease severity contributed to the effect of sex.
Detection of Clinically Important YMDD Variants
An algorithm was developed for identifying clinically important
YMDD variants with standard serum ALT and HBV DNA data,
without the need to test for YMDD-variant HBV. In patients
who have completed 24 weeks of lamivudine therapy, the
combined presence of an ALT level of 11.3 times the upper
limit of normal and an HBV DNA level of 120 pg/mL (as
determined by solution hybridization) was predictive of the
presence of YMDD variants.
During 1-year studies, the sensitivity of the algorithm for
identifying YMDD variants was modest (60 [60%] of 100
cases); however, the false-positive rate was only 3% (12 of 368
cases), and the positive predictive value was 77% (40 of 52
cases). Thus, the algorithm could identify patients with YMDD
variants who were most in need of medical attention—that is,
those with elevations in the ALT and HBV DNA levels.
This algorithm was also explored for its ability to predict
longer-term clinical outcomes in the B3018 extended-treatment
study. Of the study patients, 13 (22%) of 58 met the ALT and
HBV DNA criteria at least once during the first 2 years of
treatment, and 9 (69%) of 13 patients had YMDD variants;
ALT and HBV DNA levels remained elevated in 6 (46%) of 13
patients 3 months after satisfying the algorithm, but the levels
remained elevated in only 4 (31%) of 13 patients by the end
of treatment year 3. In 3 (23%) of 13 patients, HBeAg loss
occurred. Thus, although most HBeAg-positive patients who
met the ALT and HBV DNA criteria had detectable YMDD
variants, the algorithm was not a reliable predictor of subse-
quent changes in serologic HBV markers or necroinflammatory
activity.
DISCUSSION
As supported by reduced in vitro replication competence of
YMDD variants [15–17], clinical and laboratory findings sug-
gest that YMDD variants are functionally impaired. After la-
mivudine therapy is withdrawn from patients who harbor
YMDD variants, wild-type HBV usually reemerges within
months as the dominant virus strain. Moreover, in patients
with YMDD variants, the presence of persistently reduced se-
rum HBV DNA levels suggests that YMDD variants do not
replicate as effectively as wild-type HBV.
In our patients with chronic hepatitis B, YMDD variants
were seldom detected before 36 weeks of lamivudine therapy,
and ∼50% of patients remained YMDD-variant free after 3
years. In contrast, resistance occurs within a few months in
nearly all HIV-infected recipients of lamivudine monotherapy
[27]. Similarly, YMDD variants emerge more rapidly in im-
munocompromised liver allograft recipients [28].
In most patients, improvements in liver disease persisted in
the presence of YMDD variants if lamivudine therapy was con-
tinued. Serum HBV DNA was suppressed, and liver histologic
findings and serum ALT levels improved significantly in patients
who received lamivudine for 1 year, regardless of whether
YMDD variants emerged. After 2–4 years of lamivudine ther-
apy, serum HBV DNA and ALT levels generally remained im-
proved, compared with pretreatment levels, even among pa-
tients who harbored YMDD variants for 12 years. These
findings are supported by a recent histologic analysis, in which
both necroinflammatory activity and fibrosis were improved in
most patients who harbored YMDD variants after 2 years of
lamivudine therapy [29].
In some patients, the extended presence of YMDD variants
is associated with a slow increase in the serum HBV DNA level,
a parallel increase in the ALT level, and, sometimes, deterio-
ration of liver histologic findings [23, 24, 30]. Compared with
baseline, liver histologic findings were improved in 5 of 9 pa-
tients who harbored YMDD variants after 3 years of lamivudine
therapy, but histologic findings had deteriorated compared with
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the findings of the year 1 biopsy in 6 of these 9 patients. Thus,
after the emergence of YMDD variants, histologic responses to
lamivudine may diminish, even though they do not generally
disappear. Although, in our experience, YMDD variants were
generally benign, other reports document that, in cohorts of
liver allograft recipients, YMDD variants with enhanced rep-
lication and more-severe clinical consequences occur [28, 31].
Emergence of YMDD variants reduces or delays, but does
not prevent, HBeAg seroconversion [32]. Throughout 4 years
of lamivudine therapy, the rate of HBeAg seroconversion in
patients who harbored YMDD variants remained lower than
in patients without variants, probably a reflection of less sub-
stantial reduction in HBV replication in the variant group [19].
The similarity of adverse events in patients with or without
YMDD variants, even with extended lamivudine therapy, sug-
gests that YMDD variants have no unique pathogenic effects.
Predominantly asymptomatic ALT elevations during treatment
were somewhat more common among patients with YMDD
variants; however, these generally coincided with the return of
detectable viremia and were often associated with HBeAg se-
roconversion [33]. A similar transient increase in the ALT level
occurs sometimes after cessation of treatment in patients who
did not harbor YMDD variants, suggesting that HBV replica-
tion, rather than HBV type, is the cause.
Posttreatment ALT elevations were less frequent among pa-
tients with YMDD variants than they were among those who
did not have YMDD variants, perhaps because YMDD variants
may be less virulent than is wild-type HBV, as suggested by
reduced replication competence in vitro [15, 17]. Indeed, most
posttreatment elevations in the ALT level coincided with re-
emergence of wild-type HBV, even when YMDD-variant HBV
predominated at the end of therapy.
Baseline virus level, disease severity, and body size were as-
sociated with the emergence of YMDD variants during the first
year of lamivudine therapy. Baseline virus level, reflecting the
rate of HBV replication and, therefore, mutational frequency,
is a logical predictor of YMDD variants. Similarly, recent data
suggest that initial virologic response after 3 or 6 months of
lamivudine therapy predicts whether YMDD variants will
emerge subsequently [34, 35]. In the same vein, the association
between the level of HBV replication and liver injury may
explain the higher frequency of YMDD variants in patients with
high baseline necroinflammatory activity. Increased body size
might enhance YMDD variant frequency as a result of reduced
drug concentration; however, YMDD incidence was unaffected
by lamivudine dose in study B3009. In terms of viral factors,
whether different YMDD mutations (L180M, M204V, and
M204I [36]) are associated with different clinical expressions
is unknown. Although some have suggested that YMDD var-
iants are more likely in certain HBV genotypes [37], others
have failed to corroborate this association [38, 39].
When this study was conducted, routine clinical assays for
YMDD variants were not available. Therefore, we sought to
identify an algorithm based on routine laboratory tests to sug-
gest the presence of phenotypically relevant (i.e., associated with
recurrent hepatitis) YMDD variants in lamivudine recipients.
Even now that a clinical assay for YMDD mutants is available,
many clinicians continue to rely on ALT and HBV DNA values
in decision-making about lamivudine resistance.
Most patients with YMDD variants retain at least partial
clinical response for several years, but approaches to lamivudine
resistance will change as new antiviral agents are introduced.
The urgency with which new therapies are needed is greatest
in patients with end-stage liver disease and after liver trans-
plantation, in which additional clinical deterioration has a po-
tentially fatal outcome [40, 41]. Recently approved adefovir
dipivoxil, which has potent activity against YMDD-variant hep-
atitis B, will simplify management of infection due to such
variants in the future [42–44].
In summary, in compensated chronic hepatitis B, YMDD
variants increased with the duration of lamivudine treatment.
Despite the emergence of variants, many patients maintained
improvements in markers of HBV infection and liver injury,
although there was not necessarily histologic benefit, after sev-
eral years of YMDD-variant HBV infection.
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